NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...
NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate ...
NXP Semiconductors, Bangalore, INDIA Abstract The consumer electronic devices are becoming complex and employing multiple processors. Design of hardware and software for such a system presents lots of ...